An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry

Fabian Olsson, Simon Erridge, James Tait, Carl Holvey, Ross Coomber, Sushil Beri, Jonathan Hoare, Shaheen Khan, Mark W. Weatherall, Michael Platt, James J. Rucker, Mikael H. Sodergren*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)

Abstract

Background: There is a paucity of high-quality data on patient outcomes and safety after initiating treatment with cannabis-based medicinal products (CBMPs). The aim of this study was to assess the clinical outcomes and safety of CBMPs by analyzing patient-reported outcome measures and adverse events across a broad spectrum of chronic conditions. Research design and methods: This study analyzed patients enrolled in the UK Medical Cannabis Registry. Participants completed the EQ-5D-5L to assess health-related quality of life, Generalized Anxiety Disorder-7 (GAD-7) questionnaire to measure anxiety severity, and the Single-item Sleep Quality Scale (SQS) to rate sleep quality at baseline and follow-up after 1, 3, 6, and 12 months. Results: A total of 2833 participants met inclusion criteria. The EQ-5D-5L index value, GAD-7, and SQS all improved at each follow-up (p < 0.001). There was no difference in EQ-5D-5L index values between former or current illicit cannabis consumers and naïve patients (p > 0.050). Adverse events were reported by 474 (16.73%) participants. Conclusions: This study suggests that CBMPs are associated with an improvement in health-related quality of life in UK patients with chronic diseases. Treatment was tolerated well by most participants, but adverse events were more common in female and cannabis-naïve patients.

Original languageEnglish
Pages (from-to)257-266
Number of pages10
JournalExpert review of clinical pharmacology
Volume16
Issue number3
Early online date27 Feb 2023
DOIs
Publication statusPublished - 3 Mar 2023

Keywords

  • cannabidiol
  • Cannabis-based medicinal products
  • CBMPs
  • medical cannabis
  • tetrahydrocannabi

Fingerprint

Dive into the research topics of 'An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry'. Together they form a unique fingerprint.

Cite this